![Bruce W. Tomlinson](https://cdn.zonebourse.com/static/resize/768/576//static/images/insiders/unknown.png)
Profiel
Bruce W.
Tomlinson served as the Chief Accounting Officer, VP & Controller at InterMune, Inc. from 2009 to 2012.
He also briefly served as the Chief Financial Officer & Vice President at PDL BioPharma, Inc. in 2012.
Tomlinson received his undergraduate degree from the University of California, Los Angeles.
Eerdere bekende functies van Bruce W. Tomlinson
Bedrijven | Functie | Einde |
---|---|---|
PDL BIOPHARMA, INC. | Financieel Directeur/CFO | 30-11-2012 |
INTERMUNE INC | Comptroller/Controller/Auditor | 08-06-2012 |
Opleiding van Bruce W. Tomlinson
University of California, Los Angeles | Undergraduate Degree |
Ervaring
Beklede functies
Actief
Inactief
Beursgenoteerde bedrijven
Bedrijven in privébezit
Connecties
Eerstegraads connecties
Bedrijven verbonden in de eerste graad
Man
Vrouw
Besturend
Uitvoerend
Verwante bedrijven
Bedrijven in privébezit | 2 |
---|---|
InterMune, Inc.
![]() InterMune, Inc. BiotechnologyHealth Technology InterMune, Inc. operates as a biotechnology company that researches, develops and commercializes therapies in pulmonology and orphan fibrotic diseases. It focuses on therapies for the treatment of idiopathic pulmonary fibrosis, a progressive and fatal lung disease. The firms research programs are focused on the discovery of targeted, small-molecule therapeutics and biomarkers to treat and monitor serious pulmonary and fibrotic diseases. The company was founded in 1998 and is headquartered in South San Francisco, CA. | Health Technology |
PDL BioPharma, Inc.
![]() PDL BioPharma, Inc. BiotechnologyHealth Technology PDL BioPharma, Inc. engages in the business of developing innovative therapeutics and healthcare technologies. It operates under the Medical Devices and Income Generating Assets segments. The Medical Devices segment focuses on the sale and lease of the LENSAR laser system which includes equipment, patient interface devices, procedure licenses, training, installation, warranty, and maintenance agreements. The Income Generating Assets segment offers notes and other long-term receivables; royalty rights, hybrid notes, and royalty receivables; equity investments; and royalties from issued patents covering the humanization of antibodies. The company was founded by Cary L. Queen and Laurence Jay Korn in 1986 and is headquartered in Reno, NV. | Health Technology |